Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation

 
• By Mandy Jackson

Accera blamed the study's failure on a revised formulation for AC-1204, but the company plans to begin a second Phase III trial with an improved formulation of the drug in the second or third quarter of 2017.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from R&D

More from Scrip